Johnson & Johnson price target raised to $169 from $164 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Johnson & Johnson to $169 from $164 and keeps an Equal Weight rating on the shares after the company posted a Q1 beat, raised 2025 revenue guidance and reiterated EPS guidance. New product cycles are offsetting Stelara declines, which is a positive, and while tariffs are impacting Medtech, there is still limited visibility on potential pharma tariffs, adds the analyst following what the firm calls “all in a generally in line quarter.”